Boston Scientific (BSX) Short-Term Debt repayments (2019 - 2026)

Boston Scientific has disclosed Short-Term Debt repayments across 6 years of filings, most recently posting $259.0 million for Q1 2026.

• Short-Term Debt repayments for Q1 2026 came in at $259.0 million, down 76.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $771.0 million (down 28.81% YoY), and the FY2025 annual result was $1.6 billion, up 216.47% from the prior year.
• Short-Term Debt repayments came in at $259.0 million for Q1 2026 at Boston Scientific, up from $12.0 million in the prior quarter.
• In the past five years, Short-Term Debt repayments ranged from a high of $1.1 billion in Q1 2025 to a low of $12.0 million in Q3 2025.
• The 4-year median for Short-Term Debt repayments is $379.5 million (2025), against an average of $434.7 million.
• Across the five-year window, Short-Term Debt repayments jumped 114.88% in 2025 and plunged 76.08% in 2026, its largest moves.
• Boston Scientific's Short-Term Debt repayments stood at $250.0 million in 2022, then surged by 101.6% to $504.0 million in 2024, then plunged by 97.62% to $12.0 million in 2025, then jumped by 2058.33% to $259.0 million in 2026.
• The last three Short-Term Debt repayments figures came in at $259.0 million (Q1 2026), $12.0 million (Q3 2025), and $500.0 million (Q2 2025), per Business Quant data.